Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2023

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519

Mease P,

Helliwell P,

Silwinska-Stanczyk P,

Miakisz M,

Ostor A,

Peeva E,

Vincent MS,

Sun Q,

Sikirica V,

Winnette R,

Qiu R,

Li G,

Feng G,

Beebe JS,

Martin DA.

Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.

Keywords:

December 2022

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571

Sahin B,

Wang Z,

Hyde C,

Martin DA

Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.